Raimund Jakesz

Raimund Jakesz

Auto-generated profile, based on publicly available information

Raimund Jakesz

Division of General Surgery, Vienna Medical School, Vienna, Austria

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in The Lancet
Verified
Journal Article
Closed access
RJRaimund Jakesz
Raimund Jakesz
WJWalter Jonat
Walter Jonat
Michael GnantMichael Gnant
Michael Gnant
MMMartina Mittlboeck
Martina Mittlboeck
RGRichard Greil
Richard Greil
MKManfred Kaufmann
Manfred Kaufmann

11 December 2007 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RJRaimund Jakesz
Raimund Jakesz
RGRichard Greil
Richard Greil
Michael GnantMichael Gnant
Michael Gnant
MSMarianne Schmid
Marianne Schmid
WKWerner Kwasny
Werner Kwasny
OGOn behalf of the Austrian Breast and Colorectal Cancer Study Group
On behalf of the Austrian Breast and Colorectal Cancer Study Group
Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor letrozole reduces breast cancer recurrence. We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy. Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in which hormone receptor–positive postmenopausal patients received 5 years of adjuvant tamoxifen, with or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy. For ABCSG Trial 6a, patients who were disease free at the end of Trial 6 were randomly assigned to receive either 3 years of anastrozole or no further treatment. Efficacy data were analyzed with the use of a Cox proportional hazards regression model with two-sided P values and Kaplan–Meier curves, and tolerability data were estimated using logistic regression analysis with odds ratios and 95% confidence intervals (CIs). ABCSG Trial 6a included 856 patients. At a median follow-up of 62.3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0.62; 95% CI = 0.40 to 0.96, P = .031). Anastrozole was well tolerated, and no unexpected adverse events were reported. These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment. Further research is required to define the optimum length of extended adjuvant therapy and to investigate the possibility of tailoring this period to suit different disease types.

1 June 2002
Verified
Journal Article
Closed access
MSMonika Schindl
Monika Schindl
Stefan SchoppmannStefan Schoppmann
Stefan Schoppmann
HSHellmut Samonigg
Hellmut Samonigg
HHHubert Hausmaninger
Hubert Hausmaninger
WKWerner Kwasny
Werner Kwasny
AGAustrian Breast and Colorectal Cancer Study Group
Austrian Breast and Colorectal Cancer Study Group


1 January 2008 in Breast Care
Verified
Journal Article
Closed access
PDF file
RJRaimund Jakesz
Raimund Jakesz
The incidence of breast cancer is low in India, but rising. Breast cancer is the commonest cancer of urban Indian women and the second commonest in the rural women. Owing to the lack of awareness of this disease and in absence of a breast cancer screening program, the majority of breast cancers are diagnosed at a relatively advanced stage. The quality of care available for breast cancer patients varies widely according to where the patient is treated. Although there are some centers of excellence providing multimodality protocol-based treatment at par with the best anywhere in the world, the vast majority of breast cancer patients undergo inadequate and inappropriate treatment due to lack of high-quality infrastructure and sometimes skills, and above all financial resources. The recent emphasis on health education, early diagnosis of cancers, and more public facilities for cancer treatment are expected to bring about the much needed improvement in breast cancer care in India.

1 November 2002
Verified
Journal Article
Closed access
TBThomas Bachleitner-Hofmann
Thomas Bachleitner-Hofmann
BPBarbara Pichler-Gebhard
Barbara Pichler-Gebhard
MRMargarethe Rudas
Margarethe Rudas
Michael GnantMichael Gnant
Michael Gnant
STSusanne Taucher
Susanne Taucher
RJRaimund Jakesz
Raimund Jakesz